Update on the glutamatergic neurotransmitter system and the role of excitotoxicity in amyotrophic lateral sclerosis

Muscle and Nerve

Volumn 26, Issue 4, 2002, Pages 438-458

  Heath, Paul R ^a   Shaw, Pamela J ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Amyotrophic lateral sclerosis; Excitotoxicity; Glutamate receptors; Glutamate transporters; Neurotransmission

Indexed keywords

AMPA RECEPTOR; CALCIUM BINDING PROTEIN; CARRIER PROTEIN; CHAPERONE; CYCLOOXYGENASE 2; EXCITATORY AMINO ACID TRANSPORTER; EXCITOTOXIN; GLUTAMATE AMMONIA LIGASE; GLUTAMATE DEHYDROGENASE; GLUTAMATE RECEPTOR; GLUTAMIC ACID; KAINIC ACID RECEPTOR; NEUROTRANSMITTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE;

AMYOTROPHIC LATERAL SCLEROSIS; CELL SIZE; CEREBROSPINAL FLUID; HUMAN; METABOLISM; MITOCHONDRION; NERVE DEGENERATION; NERVE INJURY; NEUROFILAMENT; NEUROTRANSMISSION; PRIORITY JOURNAL; REVIEW;

AMINO ACID TRANSPORT SYSTEM X-AG; AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; EXCITATORY AMINO ACIDS; GLUTAMIC ACID; HUMANS; MOTOR NEURONS; NEURAL PATHWAYS; NEUROTRANSMITTER AGENTS; RECEPTORS, AMPA; RECEPTORS, GLUTAMATE; RECEPTORS, KAINIC ACID; RECEPTORS, METABOTROPIC GLUTAMATE; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 0036787803     PISSN: 0148639X     EISSN: None     Source Type: Journal    
DOI: 10.1002/mus.10186     Document Type: Review

References (213)

1. Abe K, Pan LH, Watanabe M, Konno H, Kato T, Itoyama Y. Upregulation of protein-tyrosine nitration in the anterior horn cells of amyotrophic lateral sclerosis. Neurol Res 1997;19:124-128.
2. Aihara Y, Mashima H, Onda H, Hisano S, Kasuya H, Hori T, Yamada S, Tomura H, Yamada Y, Inoue I, Kojma I, Takeda J. Molecular cloning of a novel brain-type Na(+)-dependent inorganic phosphate cotransporter. J Neurochem 2000;74:2622-2625.
3. Alagarsamy S, Marino MJ, Rouse ST, Gereau IV, RW, Heinemann SF, Conn PJ. Activation of NMDA receptors reverses desensitisation of mGluR5 in native and recombinant systems. Nat Neurosci 1999;2:234-240.
4. Alexianu ME, Ho BK, Mohamed AH, La Bella V, Smith RG, Appel SH. The role of calcium-binding proteins in selective motoneuron vulnerability in amyotrophic lateral sclerosis. Ann Neurol 1994;36:846-858.
5. Almer G, Guegan C, Teismann P, Naili A, Rosoklija G, Hayes AP, Chen C, Przedborski S. Increased expression of the proinflammatory enzyme cyclo-oxygenase 2 in amyotrophic lateral sclerosis. Ann Neurol 2001;49:176-185.
6. Aronica E, Catania MV, Geurts J, Yankaya B, Troost D. Immunohistochemical localisation of group I and II metabotropic glutamate receptors in control and ALS human spinal cord: upregulation in reactive astrocytes. Neuroscience 2001;105:509-520.
7. Arriza JL, Fairman WA, Wadiche JI, Murdoch GH, Kavanaugh MP, Amara SG. Functional comparisons of three glutamate transporter subtypes cloned from human motor cortex. J Neurosci 1994;14:5559-5569.
8. Arsac C, Raymond C, Martin-Moutot N. Immunoassays fail to detect antibodies against neuronal calcium channels in amyotrophic lateral sclerosis serum. Ann Neurol 1996;40:695-700.
9. Ayalon G, Stern-Bach Y. Functional assembly of AMPA and kainate receptors is mediated by several discrete protein-protein interactions. Neuron 2001;31:103-113.
10. Baimbridge KG, Celio MR, Rogers SH. Calcium binding proteins in the nervous system. Trends Neurosci 1992;15:303-308.
11. Ballas N, Battaglio E, Alouf F, Andres ME, Chenoweh J, Anderson ME, Burger C, Moniwa M, Davie JR, Bowers WJ, Federoff HJ, Rose DW, Rosenfeld MG, Brehm P, Mandel G. Regulation of neuronal traits by a novel transcription complex. Neuron 2001;31:353-365.
12. Banner SJ, Fray AE, Ince PG, Steward M, Cookson MR, Shaw PJ. The expression of the glutamate re-uptake transporter excitatory amino acid transporter 1 (EAAT1) in the normal human CNS and in motor neurone disease: an immunohistochemical study. Neuroscience 2001;109:27-44.
13. Beal MF, Ferrante RF, Browne SE, Matthews RT, Kowall NW, Brown RH. Increased 3-nitrotyrosine in both sporadic and familial amyotrophic lateral sclerosis. Ann Neurol 1997;42:646-654.
14. Bellochio EE, Reimes RJ, Fremeau RT Jr, Edwards RH. Uptake of glutamate into synaptic vesicles by an inorganic phosphate transporter. Science 2000;289:957-960.
15. Bensimon G, Lacomblez L, Meininder V, and the ALS/ Riluzole Study Group. A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med 1994;330:585-591.
16. Bergeron C, Beric-Maskarel K, Muntasser S, Weyer L, Somerville MJ, Percy ME. Neurofilament light and polyadenylated mRNA levels are decreased in amyotrophic lateral sclerosis motor neurones. J Neuropathol Exp Neurol 1994;53:221-230.
17. Bernard A, Khretchatisky M. Assessing the extent of RNA editing in the TM II regions of GluR5 and GluR6 kainate receptors during rat brain development. J Neurochem1994;62:2057-2060.
18. Bettler B, Boulter J, Hermans-Borgmeyer I, O'Shea Greenfield A, Deneris ES, Moll C, Borgmeyer U, Hollmann M, Heinemann S. Cloning of a novel glutamate receptor subunit GluR5: expression in the nervous system during development. Neuron 1990;5:583-595.
19. Bettler B, Mulle C. Neurotransmitter receptors II: AMPA and kainate receptors. Neuropharmacology 1995;34:123-139.
20. Biscoe TJ, Straugham DW. Microelectrophoretic studies of neurones in the cat hippocampus. J Physiol (Lond) 1966;183:341-349.
21. Bliss TV, Collingridge GL. A synaptic model of memory: long-term potentiation in the hippocampus. Nature 1993;361:31-39.
22. Borthwick GM, Johnson MA, Shaw PJ, Ince PG, Turnbull DM. Mitochondrial enzyme activity in amyotrophic lateral sclerosis: implications for the role of mitochondria in neuronal cell death. Ann Neurol 1999;46:786-790.
23. Bradford H, McIlwaine H. Ionic basis for the depolarisation of cerebral tissues by excitatory amino acids. J Neurochem 1966;13:1163-1177.
24. Braithwaite SP, Meyer G, Henley JM. Interactions between AMPA receptors and intracellular proteins. Neuropharmacology 2000;39:919-930.
25. Brorson JR, Zhang Z, Vandenberghe W. Calcium permeation of AMPA receptors in cerebellar neurones expressing Glu receptor 2. J Neurosci 1999;19:9149-9159.
26. Brown RH. Amyotrophic lateral sclerosis: recent insights from genetics and transgenic mice. Cell 1995;80:687-692.
27. Bruening W, Ror J, Giasson B, Figlewicz DA, Mushynski WE, Durham HD. Up-regulation of protein chaperones preserves viability of cells expressing toxic Cu/Zn-superoxide dismutase mutants associated with amyotrophic lateral sclerosis. J Neurochem 1999;72:693-699.
28. Bruno V, Battaglia G, Ksiazek I, van der Putten H, Catania MV, Giuffrida R, Lukic S, Leonhardt T, Inderbitzin W, Gasparini F, Kuhn R, Hampson DR, Nicoletti F, Flor PJ. Selective activation of mGlu4 metabotropic glutamate receptors is protective against excitotoxic cell death. J Neurosci 2000;20:6423-6420.
29. Burette A, Khatri L, Wyszyski M, Sheng M, Ziff EB, Weinberg RJ. Differential cellular and subcellular localisation of AMPA receptor-binding protein and glutamate receptor interacting protein. J Neurosci 2001;21:495-503.
30. Burke RE. Spinal cord: ventral horn. In: Shepherd GM, editor. The synaptic organisation of the brain. New York: Oxford University Press; 1990. p 88-132.
31. Camu W, Billiard M, Baldy-Moulinier M. Fasting plasma and CSF amino acid levels in amyotrophic lateral sclerosis: a subtype analysis. Acta Neurol Scand 1993;88:51-55.
32. Catania MV, Aronica E, Yankaya B, Troost D. Increased expression of neuronal nitric oxide synthase spliced variants in reactive astrocytes of amyotrophic lateral sclerosis human spinal cord. J Neurosci 2001;21:RC148.
33. Chittajallu R, Braithwaite SP, Clarke VRJ, Henly JM. Kainate receptors: subunits, synaptic localisation and function. Trends Pharmacol Sci 1999;20:26-35.
34. Choi DW. Calcium and excitotoxic neuronal injury. Ann N Y Acad Sci 1994;747:162-171.
35. Choi DW. Calcium: still centre stage in hypoxic-ischaemic neuronal death. Trends Neurosci 1995;18:58-60.
36. Choi DW. Excitotoxic cell death. J Neurobiol 1992;23:1261-1276.
37. Choi DW. Glutamate neurotoxicity and diseases of the nervous system. Neuron 1988;1:623-624.
38. Choi DW. Ionic dependence of glutamate toxicity in cortical cell culture. J Neurosci 1987;7:369-379.
39. Chou SM, Wang HS, Komai K. Colocalisation of NOS and SODI in neurofilament accumulation within motor neurones of amyotrophic lateral sclerosis - an immunohistochemical study. J Chem Neuroanat 1996;10:249-258.
40. Chung HJ, Xia J, Scannevin RH, Zhang X, Huganir RL. Phosphorylation of the AMPA receptor subunit GluR2 differentially regulates its interaction with PDZ domain containing proteins. J Neurosci 2001;20:7528-7267.
41. Ciabarre AM, Sullivan JM, Gahn LG, Pecht G, Heinemann S, Sevarino KA. Cloning and characterisation of X-1: a developmentally regulated member of a novel class of the ionotropic glutamate receptor family. J Neurosci 1995;15:6498-6508.
42. Constantine-Paton M. NMDA receptor as a mediator of activity dependent synaptogenesis in the developing brain. Cold Spring Harb Symp Quant Biol 1990;55:431-443.
43. Cookson MR, Shaw PJ. Oxidative stress and motor neurone disease. Brain Pathol 1999;9:165-186.
44. Cotman CW, Monaghan DT, Ottersen OP, Storm-Mathiesen J. Anatomical organisation of excitatory amino acids and their pathways. Trends Neurosci 1987;10:273-280.
45. Couratier P, Hugon J, Sindou P, Vallat JM, Dumas M. Cell culture evidence for neuronal degeneration in amyotrophic lateral sclerosis being linked to glutamate AMPA/kainate receptors. Lancet 1993;341:265-268.
46. Couratier P, Sindou P, Esclaire F, Louvel E, Hugon J. Neuroprotective effects of riluzole in ALS CSF toxicity. Neuroreport 1994;5:1012-1014.
47. Curtis DR, Koizumi K, Chemical transmitter substances in the brain of the cat. J Neurophysiol 1961;24:80-90.
48. Curtis DR, Phillis JW, Watkins JC. Chemical excitation of spinal neurones. Nature 1959;183:611-612.
49. Curtis DR, Phillis JW, Watkins JC. The chemical excitation of spinal neurones by amino acids. J Physiol (Lond) 1960;150:656-682.
50. Curtis DR, Watkins JC. The excitation and depression of spinal neurones by structurally related amino acids. J Neurochem 1960;6:117-141.
51. Das S, Sasaki YF, Rothe T, Premkumar LS, Takasu M, Crandall JE, Dikkes P, Conner DA, Rayudu PV, Cheung W, Vincent Chen H-S, Lipton SA, Nakanishi N. Increased NMDA current and spine density in mice lacking the NMDA receptor subunit NR3. Nature 1998;393:377-381.
52. Dingledine R, Borges K, Bowie D, Traynelis SF. The glutamate receptor ion channels. Pharmacol Rev 1999;51:7-61.
53. Doble A. The pharmacology and mechanism of action of riluzole. Neurology 1996;47(Suppl 4):S233-S241.
54. Doble A. The role of excitotoxicity in neurodegenerative disease: implications for therapy. Pharmacol Ther 1999;81:161-121.
55. Dong H, Zhang P, Song I, Petralia RS, Liao D, Huganir RL. Characterisation of the glutamate receptor-interacting proteins GRIP1 and GRIP2. J Neurosci 1999;19:6930-6941.
56. Drachman DB, Rothstein JD. Inhibition of cyclo-oxygenase 2 protects motor neurones in an organotypic model of amyotrophic lateral sclerosis. Ann Neurol 2000;48:792-795.
57. Dugan LL, Choi DW. Excitotoxicity, free radicals and cell membrane changes. Ann Neurol 1994;35:S17-S21.
58. Duncan MW, Steele JC, Koplin IJ, Markey SP. 2-Amino-3-methylamino-propanoic acid in cycad flour: an unlikely source of amyotropic lateral sclerosis and parkinsonismdementia of Guam. Neurology 1990;40:767-772.
59. Durham HD, Roy J, Dong L, Figlewicz DA. Aggregation of Aggregation of mutant Cu/Zn superoxide dismutase proteins in a culture model of ALS. J Neuropathol Exp Neurol 1997;56:523-530.
60. Eisen A, Pant B, Stewart H. Cortical excitability in amyotrophic lateral sclerosis: a clue to pathogenesis. Can J Neurol Sci 1993;20:11-16.
61. Fairman WA, Amara SG. Functional diversity of excitatory amino acid transporters: ion channel and transport modes. Am J Physiol 1999;277:F481-F486.
62. Ferrarese C, Pecora N, Frigo M, Appollonio I, Frattola L. Assessment of reliability and biological significance of glutamate levels in cerebrospinal fluid. Ann Neurol 1993;33:316-319.
63. Figelwicz DA, Krizus A, Martinoli MG, Meiniger V, Dib M, Rouleau GA, Julien JP. Variants of the heavy neurofilament subunit are associated with the development of amyotrophic lateral sclerosis. Hum Mol Genet 1994;3:1757-1761.
64. Flowers JM, Powell JF, Leigh PN, Andersen P, Shaw CE. Intron 7 retention and exon 9 skipping EAAT2 mRNA variants are not associated with amyotrophic lateral sclerosis. Ann Neurol 2001;49:643-649.
65. Fray AE, Ince PG, Banner SJ, Milton ID, Usher PA, Cookson MR, Shaw PJ. The expression of the glial glutamate transporter protein EAAT2 in motor neurone disease: an immunohistochemical study. Eur J Neurosci 1998;10:2481-2489.
66. Fremeau RT, Troyer MD, Pahner I, Nygaard GO, Tran CH, Reimer RJ, Bellochio EE, Fortin D, Storm-Mathsen J, Edwards RH. The expression of vesicular glutamate transporters defines two classes of excitatory synapses. Neuron 2001;31:247-260.
67. Fujita Y, Yamauchi Y, Shibayami K, Ando M, Honda M, Nagata Y. Decreased cytochrome oxidase c but unchanged Superoxide dismutase and glutathione peroxidase activities in the spinal cord of patients with amyotrophic lateral sclerosis. J Neurosci Res 1996;45:276-281.
68. Futura A, Rothstein JD, Martin LJ. Glutamate transporter protein subtypes are expressed differentially during rat CNS development. J Neurosci 1997;17:8363-8375.
69. Galindo A, Krnjevic K, Schwartz S. Microionotophoretic studies on neurones in the cuneate nucleus. J Physiol (Lond) 1967;192:359-377.
70. Gallo V, Hayes LMU, Vyklicky LJ, Winters CA, Buonanno A. Molecular cloning and developmental analysis of a new glutamate receptor subunit isoform in cerebellum. J Neurosci 1992;12:1010-1023.
71. Garner CC, Nash J, Huganir RL. PDZ domains in synapse assembly and signalling. Trends Cell Biol 2000;10:274-280.
72. Ginsberg SD, Martin LJ, Rothstein JD. Regional deafferentation down regulates sub types of glutamate transporter proteins. J Neurochem 1995;65:2800-2803.
73. Gredal O, Moller SE. Effect of branch chain amino acids on glutamate metabolism in amyotropic lateral sclerosis. J Neurol Sci 1995;129:40-43.
74. Gurney M, Cutting FB, Zhai P, Doble A, Taylor C, Andrus PK, Hall ED. Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann Neurol 1996;39:147-157.
75. Gurney ME. The use of transgenic mouse models of amyotrophic lateral sclerosis in preclinical drug studies. J Neurol Sci 1997;152(Suppl 1):S67-S73.
76. Haugeto O, Ullensvang K, Levy LN, Chaudhry FA, Honore T, Nielsen M, Lehre KP, Danbolt NC. Brain glutamate transporters form homomultimers. J Biol Chem 1996;271:27715-27722.
77. Herzog E, Bellenchi GC, Gras C, Bernard V, Ravassard P, Bedet C, Gasnier B, Giros B, Mestikawy S. The existence of a second vesicular glutamate transporter specifies subpopulations of glutamatergic neurons. J Neurosci 2001;21:RC181.
78. Hirano A. Cytopathology of amyotrophic lateral sclerosis. Adv Neurol 1991;56:91-101.
79. Hollman M, Heinemann S. Cloned glutamate receptors. Ann Rev Neurosci 1994;17:31-108.
80. Hollman M, O'Shea-Greenfield A, Rogers SW, Heinemann S. Cloning by functional expression of a member of the glutamate receptor family. Nature 1989;342:643-648.
81. Ihara K, Joo DT, Henderson J, Sattler R, Taverna FA, Lourensen S, Orser BA, Roder JC, Tymianski M. The influence of glutamate receptor 2 expression on excitotoxicity in GluR2 null mutant mice. J Neurosci 2001;21:2224-2239.
82. Ikeda K, Nagasawa M, Mori H, Araki K, Sakimura K, Watanabe M, Inoue Y, Mishina M. Cloning and expression of the epsilon 4 subunit of the NMDA receptor channel. FEBS Lett 1992;313:34-38.
83. Ince PG, Eggett CJ, Shaw PJ. The role of excitotoxicity in neurological disease. Rev Contemp Pharmacother 1997;8:195-212.
84. Ince PG, Stout N, Shaw PJ, Slade J, Hunziker W, Heizman CW, Baimbridge KG. Parvalbumin and calbindin D28K in the human motor system and in motor neuron disease. Neuropathol Appl Neurobiol 1993;19:291-299.
85. Iwasaki Y, Ikeda K, Kinoshita M. Plasma amino acid levels in patients with amyotrophic lateral sclerosis. J Neurol Sci 1992;107:219-222.
86. Iwasaki Y, Ikeda K, Shiojima T, Tagaya M, Kinoshita M. Amyotrophic lateral sclerosis cerebrospinal fluid is not toxic to cultured spinal motor neurons. Neurol Res 1995;17:393-395.
87. Jakoi ER, Sombati S, Gerwin C, DeLorenzo RJ. Excitatory amino acid receptor activation produces a selective and long lasting modulation of gene expression in hippocampal neurones. Brain Res 1992;582:282-290.
88. Kelly KA, Ho L, Winger D, Freire-Moar J, Borelli CB, Aisen PS, Pasinetti GM. Potentiation of excitotoxicity in transgenic mice overexpressing neuronal cyclo-oxygenase-2. Am J Pathol 1999;155:995-1004.
89. Kew JJM, Leigh PN, Playford ED, Passingham RE, Goldstein LH, Frackowick RS, Brooks DJ. Cortical function in amyotrophic lateral sclerosis. A positron emission tomography study. Brain 1993;116:655-680.
90. Kohler M, Burnashev N, Sakmann B, Seeburg PH. Determinants of calcium permeability in both TM I and TM II of high affinity kainate receptor channels: diversity by RNA editing. Neuron 1993;10:491-500.
91. Komuro H, Rakic P. Modulation of neuronal migration by NMDA receptors. Science 1993;260:95-97.
92. Kong KM, Xu ZS. Massive mitochondrial degeneration in motor neurones triggers the onset of amyotrophic lateral sclerosis in mice expressing a mutant SOD1. J Neurosci 1998;17:1570-1581.
93. 3H] MK-801/NMDA binding sites in spinal cord. Neurosci Lett 1993;159:191-194.
94. Kutsuwada T, Kashiwabuchi N, Mori H, Sakimura K, Kushiya E, Araki K, Meguro H, Masaki H, Kumanishi T, Arakawa M, Mishina M. Molecular diversity of the NMDA receptor channel. Nature 1992;358:36-41.
95. Laake JH, Slyngstad TA, Haug F-MS, Ottersen OP. Glutamine from glial cells is essential for the maintenance of the nerve terminal pool of glutamate: immunogold evidence from hippocampal slice cultures. J Neurochem 1995;65:871-881.
96. Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Lancet 1996;347:1425-1431.
97. Laslo P, Lipski J, Nicholson LFB, Miles GB, Funk GD. GluR2 AMPA receptor subunit expression in motor neurones at low and high risk for degeneration in amyotrophic lateral sclerosis. Exp Neurol 2001;169:461-471.
98. Lin C-LG, Bristol LA, Jin L, Dykes-Hoberg M, Crawford T, Clawson L, Rothstein JD. Aberrant RNA processing in a neurodegenerative disease: the cause for absent EAAT2, a glutamate transporter, in amyotrophic lateral sclerosis. Neuron 1998;20:589-602.
99. Lin JW, Ju W, Foster K, Lee SH, Ahmadian G, Wyszynski M, Wang YT, Sheng M. Distinct molecular echanisms and divergent endocytic pathways of AMPA receptor internalisation. Nat Neurosci 2000;3:1282-1290.
100. Lissin DV, Carroll RC, Nicoll RA, Malenka RC, von Zastrow M. Rapid, activation-induced redistribution of ionotropic glutamate receptors in cultured hippocampal neurones. J Neurosci 1999;19:1263-1272.
101. Lomeli H, Wisden W, Kohler M, Keinanen K, Sommer B, Seeburg PH. High affinity kainate and domoate receptors in the rat brain. FEBS Lett 1992;307:139-143.
102. Lopez JC. AMPA receptors: now you see them, now you don't. Nat Rev Neurosci 2001;2:5-7.
103. Louvel E, Hugon J, Doble A. Therapeutic advances in amyotrophic lateral sclerosis. Trends Pharmacol Sci 1997;18:196-203.
104. Lucas DR, Newhouse JP. The toxic effect of sodium-L-glutamate on the inner layer of the retina. Arch Opthalmol 1957;58:193-201.
105. Ludolph AC, Meyer T, Riepe MW. The role of excitotoxicity in ALS - what is the evidence? J Neurol 2000;247:S7-S16.
106. Luscher C, Frerking M. Restless AMPA receptors: implications for synaptic transmission and plasticity. Trends Neurosci 2001;24:665-670.
107. Luscher C, Nicoll RA, Malenka RC, Muller D. Synaptic plasticity and dynamic modulation of the postsynaptic membrane. Nat Neurosci 2000;3:545-550.
108. Malessa S, Leigh PN, Bertel O, Sluga E, Hornykiewicz O. Amyotrophic lateral sclerosis: glutamate dehydrogenase and transmitter amino acids in the spinal cord. J Neurol Neurosurg Psychiatry 1991;54:984-980.
109. Massieu L, Morales-Villagran A. Accumulation of extracellular glutamate by inhibition of its uptake is not sufficient for inducing neuronal damage: an in vivo microdialysis study. J Neurochem 1995;64:2262-2272.
110. Masu M, Tanabe Y, Tsuchida K, Shigemoto R, Nakanishi S. Sequence and expression of a metabotropic glutamate receptor. Nature 1991;349:760-765.
111. McDonald JW, Schoepp DD. The metabotropic excitatory amino acid agonist Is 3R-ACPD selectively potentiates N-methyl-D-aspartate induced brain injury. Eur J Pharmacol 1992;215:353-354.
112. McLennan H, Huffman RD, Marshall KC. Patterns of excitation of thalamic neurones by amino acids and by acetyl choline. Nature 1968;219:387-388.
113. Meguro H, Mori H, Araki K, Kushiya E, Kutsuwada T, Yamazaki M, Kumanishi T, Arakawa M, Sakimura K, Mishina M. Functional characterisation of a heteromeric NMDA receptor channel expressed from cloned cDNAs. Nature 1992;357:70-74.
114. Meister A, Anderson ME. Glutathione. Annu Rev Biochem 1983;52:711-760.
115. Menzies FM, Ince PG, Shaw PJ. Mitochondrial involvement in amyotrophic lateral sclerosis. Neurochem Int 2002; 40:543-551.
116. Meyer T, Framm A, Munch C, Schwalenstocker B, Fray AE, Ince PG, Stamm S, Ludolph AC, Shaw PJ. The RNA of the glutamate transporter EAAT2 is variably spliced in amyotrophic lateral sclerosis and normal individuals. J Neurol Sci 1999;170:45-50.
117. Michaelis EK. Molecular biology of glutamate receptors in the central nervous system and their role in excitotoxicity, oxidative stress and aging. Prog Neurobiol 1998;54:369-415.
118. Miller RG, Moore D, Young LA, Armon C, Barohn RJ, Bromberg MB, Bryan MB, Gelinas DF, Mendoza MC, Neville HE, Parry GJ, Petajan JH, Ravits JM, Ringel SP, Ross MA, and the WALS Study Group. Placebo-controlled trial of gabapentin in patients with amyotrophic lateral sclerosis. Neurology 1996;47:1383-1388.
119. Miller RG, Moore DH, Dronsky V, Bradley W, Barohn R, Bryan W, Prior TW, Gelinas DF, Iannacconne S, Kissel J, Leshner R, Mendoza M, Russman B, Samaha F, Smith S, and the SMA Study Group (USA). A placebo-controlled trial of gabapentin in ALS. J Neurol Sci 2001;191:127-132.
120. 2+ channels and their regulation by excitatory amino acids. Ann N Y Acad Sci 1989;568:149-158.
121. Mills KR. Motor neurone disease: studies of the corticospinal excitation of single motor neurones by magnetic brain stimulation. Brain 1995;118:971-982.
122. Milton ID, Banner SJ, Ince PG, Piggott NH, Fray AE, Thatcher N, Horne CH, Shaw PJ. Expression of the glial glutamate transporter EAAT2 in the human CNS: an immunohistochemical study. Mol Brain Res 1997;52:17-31.
123. Molander C, Xu Q, Rivero-Mellian C, Grant G. Cytoarchitectonic organisation of the spinal cord in a rat II. The cervical and thoracic cord. J Comp Neurol 1989;289:375-385.
124. Monaghan DR, Bridge RJ, Cotman CW. The excitatory amino acid receptors: their classes, pharmacology and distinct properties in the function of the central nervous system. Ann Rev Pharmacol Toxicol 1989;29:365-402.
125. Monyer H, Burnashev N, Laurie DJ, Sakmann B, Seeburg PH. Developmental and regional expression in the rat brain and functional properties of four NMDA receptors. Neuron 1994;12:529-540.
126. Monyer H, Sprengel R, Schoepfer R, Herb A, Higuchi M, Lomeli H, Burnashev N, Sakmann B, Seeman PH. Heteromeric NMDA receptors: molecular and functional distinction of subtypes. Science 1992;256:1217-1221.
127. Morrison BM, Gordon JW, Ripps ME, Morrison JH. Quantitative immunocytochemical analysis of the spinal cord in G68R superoxide dismutase transgenic mice: neurochemical correlates of selective vulnerability. J Comp Neurol 1996;373:619-631.
128. Murphy TH, Miyamoto M, Sastre A, Schnaar RL, Coyle JT. Glutamate toxicity in a neuronal cell line involves inhibition of cystine transport leading to oxidative stress. Neuron 1989;2:1547-1558.
129. Myers SJ, Peters J, Huang Y, Comer MB, Barthel F, Dingledine R. Transcriptional regulation of the GluR2 gene: neural-specific expression, multiple promoters and regulatory elements. J Neurosci 1998;18:6723-6739.
130. Nakanishi N, Alex R, Schneider NA. Alternative splicing generates functionally distinct N-methyl-D-aspartate receptors. Proc Natl Acad Sci U S A 1992;89:8552-8556.
131. Nakanishi S. Molecular diversity of glutamate receptors and implications for brain function. Science 1992;258:597-603.
132. Olney JW. Excitatory amino acids and neuropsychiatric disorders. Biol Psychiatry 1989;26:505-525.
133. Olney JW, Misra CH, deGubareff T. Cysteine-S-sulphate: brain damaging metabolite in sulfite oxidase deficiency. J Neuropathol Exp Neurol 1975;34:167-177.
134. ++ in toxic cell killing. Trends Pharmacol Sci 1989;10:281-284.
135. Osten P, Khatri L, Perez JL, Kohr G, Giese G, Daly C, Schulz TW, Lee LM, Ziff EB. Mutagenesis reveals a role for ABP/ GRIP binding to GluR2 in synaptic surface accumulation of the AMPA receptors. Neuron 2000;27:313-325.
136. Ozawa S, Kamiya H, Tsuzuki K. Glutamate receptors in the mammalian central nervous system. Prog Neurobiol 1998;54:581-618.
137. Passafaro M, Piech V, Sheng M. Subunit specific temporal and spatial patterns of AMPA receptor exocytosis in hippocampal neurons. Nat Neurosci 2001;4:917-926.
138. Patten BM, Harati Y, Acosta L, Jung S-S, Felmus MT. Free amino acid concentrations in amyotrophic lateral sclerosis. Ann Neurol 1978;3:305-309.
139. Perl TM, Bedard L, Kosatski T, Hockin JC, Todd ECD, Remis RS. An outbreak of toxic encephalopathy caused by eating mussels contaminated with domoic acid. N Engl J Med 1990;322:1775-1780.
140. Perry TL, Hansen S, Jones K. Brain glutamate deficiency in amyotrophic lateral sclerosis. Neurology 1987;37:1845-1848.
141. Perry TL, Krieger C, Hansen S, Eisen A. Amyotrophic lateral sclerosis: amino acid levels in plasma and cerebrospinal fluid. Ann Neurol 1990;28:12-17.
142. Petralia RS, Wang Y-X, Mayat E, Wenthold RJ. Glutamate receptor 2-selective antibody shows a differential distribution of calcium-permeable AMPA receptors among populations of neurons. J Comp Neurol 1997;372:356-383.
143. Pin J-P, Bockaert J. Get receptive to metabotropic glutamate receptors. Curr Opin Neurobiol 1995;5:342-349.
144. Pin JP, Duvoisin R. The inetabotropic glutamate receptors: structures and functions. Neuropharmacology 1995;34:1-26.
145. Pizzi M, Consolandi O, Memo M, Spano P. Activation of multiple metabotropic glutamate receptor subtypes prevents NMDA-induced excitotoxicity in rat hippocampal slices. Eur J Neurosci 1996;8:1516-1521.
146. Plaitakis A, Caroscio JT. Abnormal glutamate metabolism in amyotrophic lateral sclerosis. Ann Neurol 1987;22:575-579.
147. Plaitakis A, Constantakakis E, Smith J. The neuroexcitotoxic amino acids glutamate and aspartate are altered in the spinal cord and brain in amyotrophic lateral sclerosis. Ann Neurol 1988;24:446-449.
148. Prahn JHM, Lippert K, Krieglstein J. Are NMDA or AMPA/ kainate receptor agonists more efficacious in the delayed treatment of excitotoxic neuronal injury? Eur J Pharmacol 1995;292:179-189.
149. Regan RF, Panter SS, Witz A, TillyJL, Giffard RG. Ultrastructure of excitotoxic neuronal death in murine cortical culture. Brain Res 1995;705:188-198.
150. Roisen FJ, Bartfeld H, Donnenfeld H, Baxter J. Neurone specific in vitro cytotoxicity of sera from patients with amyotrophic lateral sclerosis. Muscle Nerve 1982;5:48-63.
151. Rothstein JD. Excitotoxicity hypothesis. Neurology 1996;47:S19-S25.
152. Rothstein JD, Jin L, Dykes-Hoberg M, Kuncl RW. Chronic inhibition of glutamate uptake produces a model of slow neurotoxicity. Proc Natl Acad Sci U S A 1993;90:6591-6595.
153. Rothstein JD, Kuncl RW. Neuroprotective strategies in a model of chronic glutamate mediated motor neuron toxicity. J Neurochem 1995;65:643-651.
154. Rothstein JD, Martin LJ, Kuncl RW. Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis. N Engl J Med 1992;326:1464-1468.
155. Rothstein JD, Tsai G, Kuncl RW, Clawson L, Cornblah DR, Drachman DB, Pestronk A, Stauch BL, Coyle JT. Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis. Ann Neurol 1990;28:18-25.
156. Rothstein JD, Van Kammen M, Levey AI, Martin LJ, Kuncl RW. Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann Neurol 1995;38:73-84.
157. Roy J, Minotti S, Dong L, Figlewiicz DA, Durham HD. Glutamate potentiates the toxicity of mutant Cu/Zn-superoxide dismutase in motor neurons by post-synaptic mechanisms. J Neurosci 1998;18:9673-9684.
158. Salasar Grueso EF, Roos RP. Amyotrophic lateral sclerosis and viruses. Clin Neurosci 1995;3:360-367.
159. Samarasinghe S, Virgo L, Belleroche JD. Distribution of the N-methyl-D-aspartate glutamate receptor subunit NR2A in control and amyotrophic lateral sclerosis spinal cord. Brain Res 1996;727:233-237.
160. Sans N, Racca C, Petralia RS, Wang X-Y, McCallum J, Weinthold RJ. Synapse-associated protein 97 selectively associates with a subset of AMPA receptors early in their biosynthetic pathway. J Neurosci 2001;21:7506-7516.
161. Sattler R, Xiong Z, Lu WY, Hafner M, MacDonald JF, Tymianski M. Specific coupling of NMDA receptor activation to nitric oxide neurotoxicity by PSD-95 protein. Science 1999;284:1845-1848.
162. Scannevin RH, Huganir RL. Postsynaptic organisation and regulation of excitatory synapses. Nat Rev Neurosci: 1:133141.
163. Shaw PJ. Excitatory amino acid neurotransmission, excitotoxicity and excitotoxins. Curr Opin Neurol Neurosurg 1992;5:383-390.
164. Shaw PJ, Chinnery RM, Ince PG. [3H] D-Aspartate binding sites in the normal human spinal cord and changes in motor neuron disease: a quantitative autoradiographic study. Brain Res 1994;655:195-201.
165. Shaw PJ, Eggett CJ. Molecular factors underlying selective vulnerability of motor neurons to neurodegeration in amyotrophic lateral sclerosis. J Neurol 2000;246:S1-S11.
166. Shaw PJ, Forrest V, Ince PG, Richardson JP, Wastell HJ. CSF and plasma amino acid levels in motor neurone disease: elevation of CSF glutamate in a subset of patients. Neurodegeneration 1995;4:209-216.
167. Shaw PJ, Ince PG. Glutamate, excitotoxicity and ALS. J Neurol 1997;244(2 Suppl):S3-S14.
168. 3H]MK-801. Brain Res 1994;637:297-302.
169. Shaw PJ, Williams TL, Slade JY, Eggett CJ, Ince PG. Low expression of GluR2 AMPA receptor subunit protein by human motor neurones. Neuroreport 1999;10:261-265.
170. Sheng M, Sala C. PDZ domains and the organisation of supramolecular complexes. Ann Rev Neurosci 2001;24:1-29.
171. Shi S-H, Hayashi Y, Petralia RS, Zaman SH, Wenthold RJ, Svoboda K, Malinow R. Rapid spine delivery and redistribution of AMPA receptors after synaptic NMDA receptor activation. Science 1999;284:1811-1816.
172. Siesjo BK. Calcium, ischaemia and death of brain cells. Ann N Y Acad Sci 1988;522:638-661.
173. Siliprandi R, Lipartiti M, Fadda E, Sautter J, Manev H. Activation of the glutamate metabotropic receptor protects retina against N-methyl-D-aspartate toxicity. Eur J Pharmacol 1992;219:173-174.
174. Sladeczek F, Pin JP, Recasens M, Bockaert J, Weiss S. Glutamate stimulates inositol phosphate formation in striatal neurones. Nature 1985;317:717-719.
175. Sommer B, Burnashev N, Verdoorn TA, Keinanen K, Sakmann B, Seeburg PH. A glutamate receptor channel with high affinity for domoate and kainate. EMBO J 1992;11:1651-1656.
176. Spencer PS, Palmer VS, Herman A, Asmedi A. Cycad use and motor neurone disease in Irian Jaya. Lancet 1987;2:1273-1274.
177. Stout AK, Raphael HM, Kanterewicz BI, Klann E, Reynolds IJ. Glutamate induced neurone death requires mitrochondrial calcium uptake. Nat Neurosci 1998;1:366-373.
178. Sucher NJ, Akbarian S, Chi CL, Leclerc CL, Awobuluyi M, Deitcher DL, Wu MK, Yuan JP, Jones EG, Lipton SA. Developmental and regional expression pattern of a novel NMDA receptor-like subunit (NMDAR-L) in the rodent brain. J Neurosci 1995;15:6509-6520.
179. Susel Z, Engber TM, Kuo S, Chase TN. Prolonged infusion of quinolinic acid into rat striatum in an excitotoxic model of neurodegenerative disease. Neurosci Lett 1991;121:234-238.
180. Takahashi T, Feldmeyer D, Suzuki N, Onodera K, Cull-Candy SG, Sakimura K, Mishina M. Functional correlation of NMDA receptor subunits expression with the properties of single channel and synaptic currents in the developing cerebellum. J Neurosci 1996;16:4376-4382.
181. Takamori S, Rhee JS, Rosenmund C, Jahn R. Identification of a differentiation-associated brain-specific phosphate transporter as a second vesicular glutamate transporter (VGLUT2). J Neurosci 2001;21:RC182.
182. Takuma H, Kwak S, Yoshizawa T, Kanazawa I. Reduction of GluR2 RNA editing, a molecular change that increases calcium influx through AMPA receptors, selective in the spinal ventral grey of patients with amyotrophic lateral sclerosis. Ann Neurol 1999;46:806-815.
183. Tanaka H, Grooms SY, Bennett MVL, Zukin S. The AMPAR subunit GluR2: still front and centre stage. Brain Res 2000;886:190-207.
184. Teitelbaum JS, Zatorre RJ, Carpenter S, Gendron D, Evans AC, Gjedde A, Cashman NR. Neurological sequelae of domoic acid intoxication due to the ingestion of contaminated mussels. N Engl J Med 1990;322:1781-1787.
185. Tomiyama M, Rodriguez-Puertas R, Cortes R, Christnacher A, Sommer B, Pazos A, Palacios JM, Mengod G. Differential regional distribution of AMPA receptor subunit messenger RNAs in the human spinal cord as visualised by in situ hybridisation. Neuroscience 1996;75:901-915.
186. Toms NJ, Roberts PJ, Salt TE, Staton PC. Latest eruptions in metabotropic glutamate receptors. Trends Pharmacol Sci 1996;17:429-435.
187. Traven HGL, Brodin A, Lansner O, Ekeberg P, Walles N, Grillner S. Computer simulations of NMDA and non-NMDA receptor mediated synaptic drive: sensory and supraspinal modulations of neurones and small networks. J Neurophysiol 1993;70:695-709.
188. Trotti D, Aoki M, Pasinelli P, Berger UV, Danbolt NC, Brown RH, Hediger MA. Amyotrophic lateral sclerosis linked glutamate transporter mutant has impaired glutamate clearance capacity. J Biol Chem 2001;276:576-582.
189. Trotti D, Danbolt NC, Volterra A. Glutamate transporters are oxidant vulnerable: a molecular link between oxidative and excitotoxic neurodegeneration. Trends Pharmacol Sci 1998;19:328-334.
190. Tsai G, Stauch-Slusher B, Sim L, Hedreen JC, Rothstein JD, Kuncl R, Coyle JT. Reductions in acidic amino acids and N-acetyl-aspartyl-glutamate (NAAG) in amyotrophic lateral sclerosis CNS. Brain Res 1990;556:151-156.
191. Turrigiano GG. AMPA receptors unbound: membrane cycling and synaptic plasticity. Neuron 2000;26:5-8.
192. 2+-permeable AMPA receptors and selective vulnerability of motor neurons. J Neurol Sci 2000;180:29-34.
193. Vandenberg RJ. Molecular pharmacology and physiology of glutamate transporters in the central nervous system. Clin Exp Pharmacol Physiol. 1998;25:393-400.
194. Vandenberghe W, Ihle EC, Patneau DK, Robberecht W, Brorson JR. AMPA receptor current density, not desensitisation, predicts selective motor neurone vulnerability. J Neurosci 2000;20:7158-7166.
195. Vandenberghe W, Robberecht W, Brorson JR. AMPA receptor calcium permeability, GluR2 expression, and selective motor neurone vulnerability. J Neurosci 1999;20:123-132.
196. Vartiainen N, Tikka T, Keinanen R, Chan PH, Koistinaho J. Glutamatergic receptors regulate expression, phosphorylation and accumulation of neurofilaments in spinal cord neurons. Neuroscience 1999;93:1123-1133.
197. Virgo L, Belleroche JD. Induction of the immediate early gene c-jun in human spinal cord in amyotrophic lateral sclerosis with concomitant loss of NMDA receptor NR-1 and glycine transporter mRNA. Brain Res 1995;676:196-204.
198. Watanabe M, Inoue Y, Sakimura K, Mishina M. Developmental changes in distribution of NMDA receptor channel subunit mRNAs. Neuroreport 1992;3:1138-1140.
199. Watkins JC, Evans RH. Excitatory amino acid transmitters. Ann Rev Pharmacol Toxicol 1981;21:165-204.
200. Whetsell WO. Current concepts in excitotoxicity. J Neuropathol Exp Neurobiol 1996;5:1-13.
201. Whetsell WO, Schwartz R. Prolonged exposure to submicromolar concentrations of quinolinic acid causes excitotoxic damage in organotypic cultures of rat cortocostriatal system. Neurosci Lett 1989;97:271-275.
202. White A, Handler P, Smith EL. Principles of biochemistry: New York: McGraw-Hill; 1976. p 656-679.
203. Williams TL, Day NC, Ince PG, Kamboj RK, Shaw PJ. Calcium permeable α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptors: a molecular determinant of selective vulnerability in amyotrophic lateral sclerosis. Ann Neurol 1997;42:200-207.
204. Williams TL, Ince PG, Oakley AE, Shaw PJ. An immunocytochemical study of the distribution of AMPA selective glutamate receptor subunits in the normal human motor system. Neuroscience 1996;74:185-188.
205. Williamson TL, Bruijn LI, Zhu Q, Anderson KL, Anderson SD, Julien JP, Cleveland DW. Absence of neurofilaments reduces the selective vulnerability of motor neurons and slows disease caused by a familial amyotrophic lateral sclerosis-linked superoxide dismutase 1 mutant. Proc Natl Acad Sci U S A 1998;95:9631-9636.
206. Wolfgram F, Myers L. Amyotrophic lateral sclerosis: effect of serum on anterior horn cells in culture. Science 1973;179:579-580.
207. Wong PC, Pardo CA, Borchett DR, Lee MK, Copeland NG, Jenkins NA, Sisodia SS, Cleveland DW, Price DL. An adverse property of familial ALS-linked SOD1 mutation causes motor neuron disease characterised by vacuolar degeneration of mitochondria. Neuron 1995;14:1105-1116.
208. Xia J, Zhang X, Staudinger J, Huganir RL. Clustering of AMPA receptors by the synaptic PDZ-domain containing protein PICK-1. Neuron 1999;22:179-187.
209. Ye B, Liao D, Zhang X, Zhang P, Dong H, Huganir RL. GRASP-1: a neuronal RasGEF associated with the AMPA receptor/GRIP complex. Neuron 2000;26:603-617.
210. Young AB. What's the excitement about excitatory amino acids in amyotrophic lateral sclerosis. Ann Neurol 1990;28:9-11.
211. Young AB, Penney JB. Pharmacological aspects of motor dysfunction. In: Asbury AK, McKhann GM, McDonald WI, editors. Diseases of the nervous system. Volume 1, Clinical neurobiology. Philadephia: Saunders; 1992. p 342-352.
212. Zhou Q, Xiao MY, Nicoll RA. Contribution of cytoskeleton to the internalisation of AMPA receptors. Proc Natl Acad Sci U S A 2001;98:1261-1266.
213. Zukin RS, Bennett MVL. Alternatively spliced isoforms of the NMDAR1 receptor subunit. Trends Neurosci 1995;18:306-313.